Related coverage linked through entity extraction aliases.
Aug 03, 2026
AstraZeneca reported strong Q1 2026 results with 8% revenue growth and 12% operating profit growth, driven by its oncology portfolio and pipeline progress. The company also saw unusual options activity and maintained full-year guidance. Key oncology brands including Imfinzi and Enhertu showed double-digit growth.
Aug 01, 2026
Groupama Asset Management acquired a new stake in AstraZeneca, while ING Groep NV trimmed its position, reflecting mixed institutional activity. Amundi, Janus Henderson, and Royal Bank of Canada significantly increased their holdings in the first quarter. Institutional investors and hedge funds own 20.35% of AstraZeneca's stock.
Mar 16, 2026
Multiple institutional investors expanded their positions in AstraZeneca during the third quarter of 2025, with several funds increasing holdings by over 100% according to SEC filings.
Feb 23, 2026
Multiple institutional investors expanded their stakes in AstraZeneca during the third quarter of 2025, with the stock trading near its 52-week high and maintaining a "Moderate Buy" rating from analysts.
Feb 14, 2026
Multiple institutional investors expanded their positions in AstraZeneca during the third quarter, with AMG National Trust Bank, Cibc World Market Inc., and Advisors Asset Management Inc. increasing holdings by approximately 20%.
Feb 14, 2026
Multiple institutional investors modified their positions in AstraZeneca during the third quarter, with new stakes and adjustments reported in SEC filings. The company announced a dividend of $1.595 per share payable March 23rd.
